All In Biotech

Drug Trial Radar · NCT02986100

Absorption, Metabolism, and Excretion Following a Single Oral Dose of [14C]-Rucaparib

An Open-Label, Non-Randomized, Phase I Study to Assess the Absorption, Metabolism, and Excretion Following a Single Oral Dose of [14C]-Rucaparib in Patients With Advanced Solid Tumors

Last checked: Nov 20, 2026Latest source record: Jun 9, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

6

Actual

Start

Nov 2016

Primary completion

Dec 2017

Study completion Sep 2018

Sponsor

Lead sponsor
pharmaand GmbHIndustry
Sponsor type
Industry
First posted
Dec 8, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to characterize the mass balance, absorption, metabolism, and elimination pathways of orally administered \[14C\] rucaparib followed by cycle by cycle treatment with rucaparib continuing until disease progression or other reason for discontinuation

Conditions

  • Solid Tumor

Interventions

  • C-14 labeled RucaparibDrug

    Each dosage unit consists of a hard gelatin capsule filled with cold rucaparib camsylate and \[14C\]-rucaparib camsylate salt. Each capsule contains approximately 150 mg rucaparib (free base weight) and approximately 35 µCi of \[14C\]-rucaparib. Each patient will ingest four capsules in the fasted state for a total dose of 600 mg rucaparib (free base weight) with approximately 140 µCi of \[14C\]-rucaparib

  • RucaparibDrug

    200 \& 300 mg tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetics of 14C-labeled rucaparib (radioactivity in whole blood and plasma): tmaxTime frame: Days 1-13
  2. Pharmacokinetics of 14C-labeled rucaparib(Radioactivity in whole blood and plasma): CmaxTime frame: Days 1-13
  3. Pharmacokinetics of 14C-labeled rucaparib(Radioactivity in whole blood and plasma): t1/2Time frame: Days 1-13
  4. Pharmacokinetics of 14C-labeled rucaparib(Radioactivity in whole blood and plasma): AUCTime frame: Days 1-13
  5. Pharmacokinetics of 14C-labeled rucaparib(Radioactivity in whole blood and plasma): CL/FTime frame: Days 1-13
  6. Pharmacokinetics of 14C-labeled rucaparib(Radioactivity in whole blood and plasma): V/FTime frame: Days 1-13
  7. Excretion rate of 14C-labeled rucaparib(radioactivity in feces)Time frame: Days 1-13
  8. Excretion rate of 14C-labeled rucaparib(radioactivity in urine)Time frame: Days 1-13
  9. Pharmacokinetics of rucaparib (in urine): CLRTime frame: Days 1-13
  10. Excretion rate of 14C-labeled rucaparib(radioactivity in vomit, if applicable)Time frame: Days 1-13
  11. Metabolite identification of rucaparib in plasma, urine and fecesTime frame: Days 1-13
  12. Cumulative whole blood:plasma ratio calculated for CmaxTime frame: Days 1-13
  13. Cumulative whole blood:plasma ratio calculated for AUC0-tlastTime frame: Day 1-13
  14. Cumulative whole blood:plasma ratio calculated for AUCinfTime frame: Day 1-13

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • PRA Magyarország Kft.

    Budapest, Rottenbiller Utca 13, Hungary

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.